SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Seeking Alpha / 10 hours ago 1 Views
Comments